Doheny Asset Management CA Decreases Holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Doheny Asset Management CA reduced its position in Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) by 17.3% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 24,178 shares of the biopharmaceutical company’s stock after selling 5,072 shares during the period. Doheny […]

Related Keywords

Ireland ,Belgium ,Japan ,Switzerland ,United States ,Michaelj Labarre , ,Goldman Sachs Group ,Nasdaq ,Vanguard Personalized Indexing Management ,Charles Schwab Investment Management Inc ,Associates Corp ,Hightower Advisors ,Halozyme Therapeutics Inc ,Pathstone Family Office ,Exchange Commission ,Doheny Asset Management ,Halozyme Therapeutics ,Free Report ,Asset Management ,Tower Advisors ,Family Office ,Personalized Indexing Management ,Charles Schwab Investment Management ,Schwab Investment Management ,Get Free Report ,Halozyme Therapeutics Daily ,Nasdaq Halo ,Halo ,Medical ,40637h10 ,Sec Filings ,13f ,Hedge Fund Holdings ,Institutional Investor Holdings ,